Recent Research Analysts’ Ratings Updates for Maravai LifeSciences (MRVI)

Maravai LifeSciences (NASDAQ: MRVI) has recently received a number of price target changes and ratings updates:

• 11/14/2024 – Maravai LifeSciences is now covered by analysts at Wolfe Research. They set a “peer perform” rating on the stock.
• 11/8/2024 – Maravai LifeSciences had its price target lowered by analysts at Royal Bank of Canada from $17.00 to $13.00. They now have an “outperform” rating on the stock.
• 11/8/2024 – Maravai LifeSciences had its price target lowered by analysts at Robert W. Baird from $10.00 to $9.00. They now have an “outperform” rating on the stock.
• 11/8/2024 – Maravai LifeSciences had its “market perform” rating reaffirmed by analysts at William Blair.
• 10/8/2024 – Maravai LifeSciences had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $8.00 to $7.00. They now have a “neutral” rating on the stock.

Maravai LifeSciences Price Performance

Shares of NASDAQ:MRVI traded up $0.41 on Tuesday, reaching $5.70. The company’s stock had a trading volume of 2,270,383 shares, compared to its average volume of 2,259,340. The company has a 50-day simple moving average of $7.29 and a 200 day simple moving average of $8.24. Maravai LifeSciences Holdings, Inc. has a 52-week low of $4.28 and a 52-week high of $11.56. The company has a debt-to-equity ratio of 0.89, a quick ratio of 9.94 and a current ratio of 10.74. The company has a market cap of $1.44 billion, a P/E ratio of -3.48 and a beta of 0.02.

Insider Buying and Selling

In related news, insider Carl Hull purchased 175,000 shares of the stock in a transaction that occurred on Monday, November 11th. The stock was bought at an average cost of $5.64 per share, for a total transaction of $987,000.00. Following the completion of the transaction, the insider now directly owns 175,000 shares in the company, valued at $987,000. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 0.63% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Maravai LifeSciences

A number of large investors have recently made changes to their positions in MRVI. Creative Planning boosted its position in shares of Maravai LifeSciences by 4.4% during the third quarter. Creative Planning now owns 44,943 shares of the company’s stock valued at $373,000 after buying an additional 1,881 shares during the period. GAMMA Investing LLC boosted its holdings in Maravai LifeSciences by 310.2% during the 2nd quarter. GAMMA Investing LLC now owns 3,585 shares of the company’s stock valued at $26,000 after acquiring an additional 2,711 shares during the period. Price T Rowe Associates Inc. MD grew its position in Maravai LifeSciences by 5.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 73,595 shares of the company’s stock valued at $639,000 after acquiring an additional 3,575 shares during the last quarter. Kornitzer Capital Management Inc. KS increased its stake in Maravai LifeSciences by 0.7% in the third quarter. Kornitzer Capital Management Inc. KS now owns 519,890 shares of the company’s stock worth $4,320,000 after purchasing an additional 3,725 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Maravai LifeSciences during the second quarter valued at $32,000. 50.25% of the stock is owned by hedge funds and other institutional investors.

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.